BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,349 | +0.6% | 190,541 | 0.0% | 0.01% | 0.0% |
| Q2 2023 | $1,341 | +70.2% | 190,541 | +101.8% | 0.01% | +50.0% |
| Q1 2023 | $788 | -30.8% | 94,440 | -4.7% | 0.01% | -33.3% |
| Q4 2022 | $1,138 | -99.9% | 99,086 | -5.5% | 0.01% | -10.0% |
| Q3 2022 | $1,321,000 | +19.1% | 104,829 | 0.0% | 0.01% | +25.0% |
| Q2 2022 | $1,109,000 | -35.0% | 104,829 | 0.0% | 0.01% | -20.0% |
| Q1 2022 | $1,705,000 | +17.9% | 104,829 | 0.0% | 0.01% | +42.9% |
| Q4 2021 | $1,446,000 | -4.0% | 104,829 | 0.0% | 0.01% | -12.5% |
| Q3 2021 | $1,506,000 | – | 104,829 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |